TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators

被引:23
作者
Chen, YW [1 ]
Smith, ML [1 ]
Chiou, GX [1 ]
Ballaron, S [1 ]
Sheets, MP [1 ]
Gubbins, E [1 ]
Warrior, U [1 ]
Wilkins, J [1 ]
Surowy, C [1 ]
Nakane, M [1 ]
Carter, GW [1 ]
Trevillyan, JM [1 ]
Mollison, K [1 ]
Djuric, SW [1 ]
机构
[1] Abbott Labs, Abbott Pk, IL 60064 USA
关键词
immunomodulator; IL-2; cytokines; RNA protection assay; ELISA; Ca2+-dependence;
D O I
10.1016/S0008-8749(03)00005-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In order to discover novel immunomodulators for application in treating autoimmune diseases, a stable Jurkat transfectant was constructed in which luciferase reporter gene is driven by a full-length IL-2 promotor. A chemical library was screened to identify compounds that inhibited luciferase expression in Jurkat transfectants stimulated with PMA and ionomycin. A class of compounds (bis-trifluoromethyl pyrazole, BTPs) was identified from this screen. BTPs were shown to inhibit anti-CD3 and anti-CD28 antibody-induced IL-2 secretion, mixed lymphocyte reaction, and Con A-induced T cell proliferation in normal human peripheral blood T cells. In addition, mRNA levels of IL-4, IL-5, IL-9, IL-10, IL-13, IL-15, and IFN-gamma were markedly inhibited by BTPs in peripheral blood mononuclear cells stimulated by Con A as determined by multi-probe RNA protection assay. Furthermore, IL-2, IL-4, IL-5, and IFN-gamma secretion by Hut 78 cells or CD3(+) T cells stimulated with PMA plus ionomycin or anti-CD3 antibody plus PMA were inhibited in a concentration-dependent manner by BTPs. Therefore, BTPs inhibit a wide spectrum of cytokine production including TH1 and TH2 type cytokines. Taken together, these compounds may be useful for treating autoimmune diseases and organ transplant rejection. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:134 / 142
页数:9
相关论文
共 22 条
[1]   3,5-bis(trifluoromethyl)pyrazoles: A novel class of NFAT transcription factor regulator [J].
Djuric, SW ;
BaMaung, NY ;
Basha, A ;
Liu, HQ ;
Luly, JR ;
Madar, DJ ;
Sciotti, RJ ;
Tu, NP ;
Wagenaar, FL ;
Wiedeman, PE ;
Zhou, X ;
Ballaron, S ;
Bauch, J ;
Chen, YW ;
Chiou, XG ;
Fey, T ;
Gauvin, D ;
Gubbins, E ;
Hsieh, GC ;
Marsh, KC ;
Mollison, KW ;
Pong, M ;
Shaughnessy, TK ;
Sheets, MP ;
Smith, M ;
Trevillyan, JM ;
Warrior, U ;
Wegner, CD ;
Carter, GW .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (16) :2975-2981
[2]  
Elmer D S, 1996, J Transpl Coord, V6, P122
[3]   INHIBITION OF T-LYMPHOCYTE ACTIVATION BY A NOVEL P56(LCK) TYROSINE KINASE INHIBITOR [J].
FALTYNEK, CR ;
WANG, S ;
MILLER, D ;
MAUVAIS, P ;
GAUVIN, B ;
REID, J ;
XIE, W ;
HOEKSTRA, S ;
JUNIEWICZ, P ;
SARUP, J ;
LEHR, R ;
SAWUTZ, DG ;
MURPHY, D .
JOURNAL OF ENZYME INHIBITION, 1995, 9 (02) :111-122
[4]   Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - Study of Lck- and FynT-dependent T cell activation [J].
Hanke, JH ;
Gardner, JP ;
Dow, RL ;
Changelian, PS ;
Brissette, WH ;
Weringer, EJ ;
Pollok, K ;
Connelly, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) :695-701
[5]  
Hashida T, 2001, Rinsho Byori, V49, P662
[6]  
KAHAN BD, 1993, TRANSPLANT P, V25, P508
[7]  
Klintmalm G B, 1995, Liver Transpl Surg, V1, P11
[8]  
MCMASTER P, 1993, TRANSPLANT P, V25, P2684
[9]   Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation [J].
Moreno, M ;
Manzanares, C ;
Castellano, F ;
Medina, E ;
Urruzuno, P ;
Camarena, C ;
Manzanares, J ;
Jara, P .
THERAPEUTIC DRUG MONITORING, 1998, 20 (04) :376-379
[10]  
MORRIS RE, 1993, THER DRUG MONIT, V17, P564